Compare ECF & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ECF | ARMP |
|---|---|---|
| Founded | 1986 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.2M | 156.4M |
| IPO Year | N/A | 1996 |
| Metric | ECF | ARMP |
|---|---|---|
| Price | $12.45 | $4.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 16.2K | ★ 263.2K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 6.42% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $27.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.33 | $2.35 |
| 52 Week High | $13.85 | $14.98 |
| Indicator | ECF | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 40.59 | 39.57 |
| Support Level | $12.15 | $3.48 |
| Resistance Level | $12.60 | $7.67 |
| Average True Range (ATR) | 0.16 | 0.52 |
| MACD | -0.01 | 0.16 |
| Stochastic Oscillator | 27.02 | 55.33 |
Ellsworth Growth and Income Fund Ltd operate as a closed-end, diversified management investment company. Its investment objective is to provide income and the potential for capital appreciation, which objectives the Fund considers to be relatively equal over the long term due to the nature of the securities in which it invests. The company invests in convertible and equity securities. It invests in various sectors, such as healthcare, financial services, computer software and services, energy and utilities, real estate investment trusts, semiconductors, telecommunications, business services, food and beverage, consumer products, transportation, consumer services among others.
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.